The Japanese automaker enjoyed an important advantage that allowed it to attract consumers interested in less polluting vehicles. Toyota (TM) – Get Toyota Motor Corporation Report is on one knee. The Japanese automaker has enjoyed a Read more…
The impact of British politics is once again dominating UK markets. Numerous cabinet resignations and the demand for Boris Johnson to step down have proved to be a driving force for GBP currency pairs and Read more…
Bitcoin is up around 1% in 24 hours to $20,400. Ethereum added 3.2%, while other top 10 altcoins gained between 0.7% (Dogecoin) and 2.8% (XRP). Buyers have braced themselves on the back of positive stock Read more…
The British pound is in positive territory today. GBP/USD is trading at 1.1977, up 0.46%. There are no tier-1 releases out of the UK today, but investors are glued to the scintillating political drama at Read more…
As noted in accounts of ECB’s June 8-9 monetary policy meeting, “most members” supported to signal the 25bps rate hike at the July meeting. Starting the rate-hiking cycle with a step of this magnitude was Read more…
Account of the monetary policy meeting of the Governing Council of the European Central Bank held in Amsterdam on Wednesday and Thursday, 8-9 June 2022 1. Review of financial, economic and monetary developments and policy Read more…
The Chevrolet Corvette was the model with the fewest problems. Here’s how 33 vehicle brands ranked in J.D. Power’s Initial Quality Study. Do you find yourself driving down the road shouting at your Siri, stabbing Read more…
Hints of a rate hike pause, buried deep in yesterday’s Fed minutes, could lift U.S. stocks to a fourth consecutive session of modest gains. U.S. equity futures bumped higher Thursday, potentially extending a modest three-day Read more…
Software giant Microsoft is seeking regulatory approval for an acquisition to cement its prominent role in videogames. Microsoft (MSFT) – Get Microsoft Corporation Report just took a hit. The software giant will have to wait before Read more…
Merck is reportedly eying cancer drug specialists Seagen as it looks to replace revenue from its Keytruda blockbuster, which loses patent exclusivity in 2028. Seagen (SGEN) – Get Seagen Inc. Report shares powered higher Thursday following Read more…